Melioidosis in a patient on monoclonal antibody therapy for psoriatic arthritis

Robert James Commons, R Grivas, Bart Currie

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Melioidosis is caused by the environmental bacterium Burkholderia pseudomallei and can present with severe sepsis. Predisposing risk factors are present in 80% of cases. Monoclonal antibodies are increasingly prescribed for varied medical conditions. This report describes the first known case of melioidosis in a patient whose only risk factor for disease is treatment with a monoclonal antibody. Prescribers of monoclonal antibodies and other immunosuppressants should ensure that their patients are aware of the potential risk of melioidosis prior to travel and the precautions that should be taken.
Original languageEnglish
Pages (from-to)1245-1246
Number of pages2
JournalInternal Medicine Journal
Volume44
Issue number12a
DOIs
Publication statusPublished - Dec 2014

Fingerprint

Melioidosis
Psoriatic Arthritis
Monoclonal Antibodies
Burkholderia pseudomallei
Immunosuppressive Agents
Causality
Sepsis
Therapeutics
Bacteria

Cite this

Commons, Robert James ; Grivas, R ; Currie, Bart. / Melioidosis in a patient on monoclonal antibody therapy for psoriatic arthritis. In: Internal Medicine Journal. 2014 ; Vol. 44, No. 12a. pp. 1245-1246.
@article{ede45dd0a14c471fb984ce57ab7c9f52,
title = "Melioidosis in a patient on monoclonal antibody therapy for psoriatic arthritis",
abstract = "Melioidosis is caused by the environmental bacterium Burkholderia pseudomallei and can present with severe sepsis. Predisposing risk factors are present in 80{\%} of cases. Monoclonal antibodies are increasingly prescribed for varied medical conditions. This report describes the first known case of melioidosis in a patient whose only risk factor for disease is treatment with a monoclonal antibody. Prescribers of monoclonal antibodies and other immunosuppressants should ensure that their patients are aware of the potential risk of melioidosis prior to travel and the precautions that should be taken.",
keywords = "adalimumab, amoxicillin plus clavulanic acid, ceftazidime, cotrimoxazole, doxycycline, etanercept, ustekinumab, antiinfective agent, antirheumatic agent, monoclonal antibody, adult, agitation, Article, backache, Burkholderia pseudomallei, case report, chronic pain, computer assisted tomography, coughing, crackle, disease exacerbation, drug megadose, drug substitution, drug treatment failure, drug withdrawal, dyspnea, eradication therapy, fever, headache, human, infection risk, leukoencephalopathy, male, melioidosis, middle aged, myalgia, neck pain, nuclear magnetic resonance imaging, psoriasis, psoriatic arthritis, risk assessment, Arthritis, Psoriatic, immunology, isolation and purification, microbiology, risk factor, treatment outcome, Amoxicillin-Potassium Clavulanate Combination, Anti-Infective Agents, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Humans, Male, Melioidosis, Middle Aged, Risk Factors, Treatment Outcome, Trimethoprim-Sulfamethoxazole Combination",
author = "Commons, {Robert James} and R Grivas and Bart Currie",
year = "2014",
month = "12",
doi = "10.1111/imj.12610",
language = "English",
volume = "44",
pages = "1245--1246",
journal = "Internal Medicine Journal",
issn = "1444-0903",
publisher = "Wiley-Blackwell",
number = "12a",

}

Melioidosis in a patient on monoclonal antibody therapy for psoriatic arthritis. / Commons, Robert James; Grivas, R; Currie, Bart.

In: Internal Medicine Journal, Vol. 44, No. 12a, 12.2014, p. 1245-1246.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Melioidosis in a patient on monoclonal antibody therapy for psoriatic arthritis

AU - Commons, Robert James

AU - Grivas, R

AU - Currie, Bart

PY - 2014/12

Y1 - 2014/12

N2 - Melioidosis is caused by the environmental bacterium Burkholderia pseudomallei and can present with severe sepsis. Predisposing risk factors are present in 80% of cases. Monoclonal antibodies are increasingly prescribed for varied medical conditions. This report describes the first known case of melioidosis in a patient whose only risk factor for disease is treatment with a monoclonal antibody. Prescribers of monoclonal antibodies and other immunosuppressants should ensure that their patients are aware of the potential risk of melioidosis prior to travel and the precautions that should be taken.

AB - Melioidosis is caused by the environmental bacterium Burkholderia pseudomallei and can present with severe sepsis. Predisposing risk factors are present in 80% of cases. Monoclonal antibodies are increasingly prescribed for varied medical conditions. This report describes the first known case of melioidosis in a patient whose only risk factor for disease is treatment with a monoclonal antibody. Prescribers of monoclonal antibodies and other immunosuppressants should ensure that their patients are aware of the potential risk of melioidosis prior to travel and the precautions that should be taken.

KW - adalimumab

KW - amoxicillin plus clavulanic acid

KW - ceftazidime

KW - cotrimoxazole

KW - doxycycline

KW - etanercept

KW - ustekinumab

KW - antiinfective agent

KW - antirheumatic agent

KW - monoclonal antibody

KW - adult

KW - agitation

KW - Article

KW - backache

KW - Burkholderia pseudomallei

KW - case report

KW - chronic pain

KW - computer assisted tomography

KW - coughing

KW - crackle

KW - disease exacerbation

KW - drug megadose

KW - drug substitution

KW - drug treatment failure

KW - drug withdrawal

KW - dyspnea

KW - eradication therapy

KW - fever

KW - headache

KW - human

KW - infection risk

KW - leukoencephalopathy

KW - male

KW - melioidosis

KW - middle aged

KW - myalgia

KW - neck pain

KW - nuclear magnetic resonance imaging

KW - psoriasis

KW - psoriatic arthritis

KW - risk assessment

KW - Arthritis, Psoriatic

KW - immunology

KW - isolation and purification

KW - microbiology

KW - risk factor

KW - treatment outcome

KW - Amoxicillin-Potassium Clavulanate Combination

KW - Anti-Infective Agents

KW - Antibodies, Monoclonal, Humanized

KW - Antirheumatic Agents

KW - Humans

KW - Male

KW - Melioidosis

KW - Middle Aged

KW - Risk Factors

KW - Treatment Outcome

KW - Trimethoprim-Sulfamethoxazole Combination

U2 - 10.1111/imj.12610

DO - 10.1111/imj.12610

M3 - Article

VL - 44

SP - 1245

EP - 1246

JO - Internal Medicine Journal

JF - Internal Medicine Journal

SN - 1444-0903

IS - 12a

ER -